Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse Clinical Trial

Official title: Real-world Evidence of Carfilzomib, Lenalidomide, Dexamethasone Combination Therapy in Korean Relapsed and/or Refractory Multiple Myeloma Patients

Status Not yet recruiting

Clinical Trial Summary

Research question: Is KRd therapy effective and safe in the real-world Asian patients?

Primay objective: To evaluate the effectiveness of KRd in RRMM patients

Secondary objectives:

To evaluate the effectiveness of investigational treatment strategy by

• PFS difference according to the high-risk disease subgroups and previous treatment

• OS

• Overall response rate and clinical benefit rate

• Duration of response To evaluate the safety and tolerability of KRd in RRMM patients

Clinical Trial Description

Key study variables:

Demographic data, ISS, R-ISS, cytogenetic abnormalities on FISH and G-banding, previous treatment regimens, response to previous treatment regimens, existence of extramedullary plasmacytoma, MM-related symptoms, whether or not M protein has increased twice or more in 2-3 months at the time of KRd commencement, response to KRd therapy, duration of KRd treatment, adverse events during KRd therapy, disease progression and progression date, survival, and censored date or day of death ;

Related Conditions & MeSH terms

• Multiple Myeloma
• Multiple Myeloma in Relapse
• Multiple Myeloma, Refractory
• Neoplasms, Plasma Cell

• NCT number: NCT05495620
• Study type: Observational
• Source: Dong-A University Hospital
• Contact: Ji Hyun Lee, MD, Ph.D
• Phone: 82-51-240-2915
• Email: hidrleejh@dau.ac.kr
• Status: Not yet recruiting
• Start date: August 1, 2022
• Completion date: September 30, 2023